Go offline with the Player FM app!
ASCO 2022: What’s New in Mantle Cell Lymphoma
Manage episode 333078084 series 3264057
In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:
- Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
- Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
- Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
- Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies
Presenters:
Tycel J. Phillips, MD
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan
Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4
90 episodes
Manage episode 333078084 series 3264057
In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:
- Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
- Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
- Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
- Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies
Presenters:
Tycel J. Phillips, MD
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan
Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4
90 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.